In relapsed/refractory DLBCL, the timing of relapse is a critical factor in determining the next line of therapy. Patients who relapse within 12 months are preferred candidates for CAR-T therapy. Those relapsing after 12 months may first undergo salvage chemotherapy followed by an autologous stem cell transplant if they respond.

An exploratory strategy for DLBCL patients involves using ctDNA to detect minimal residual disease after CAR T-cell therapy. This allows for early intervention with bispecific antibodies when the disease burden is low, potentially preventing full clinical progression, a shift from reactive to proactive treatment.

Data from both DLBCL and follicular lymphoma studies show that recent bendamustine exposure negatively impacts T-cell quality, leading to poorer CAR T-cell therapy outcomes. This effect is most pronounced if the drug was given within a year of T-cell collection, making it a critical factor in long-term treatment sequencing.

The 'brain to vein time'—from identifying a relapse to CAR T infusion—is critical. Early referral allows the specialty center to manage complex logistics like insurance authorization, organ function optimization, and patient travel, which can be significant barriers to care. Delays can mean a patient's condition deteriorates past the point of eligibility.

The TRANSFORM study quantifies the critical importance of therapy timing. DLBCL patients receiving Liso-cel CAR-T as a second-line treatment had a 95% two-year overall survival, which dropped significantly to 78% for patients who received it third-line after crossover from the standard-of-care arm.

The next major shift for CAR T-cell therapy is its integration into frontline treatment. Instead of being reserved for relapse, it's being tested as a consolidation therapy that could replace the standard two to three years of maintenance chemotherapy, dramatically shortening treatment duration.

For patients who previously received immunotherapy (IO), a recurrence more than 12 months after completing treatment makes re-challenging with an IO agent a reasonable option. The likelihood of benefit is lower if the recurrence is within 6-12 months and minimal if under 6 months.

Experts vehemently state that patients ineligible for autologous stem cell transplant are not necessarily ineligible for CAR-T therapy. This corrects a critical misconception, urging community oncologists to refer these patients for CAR-T evaluation as they may still be candidates.

Instead of treating relapsed lymphoma, Allogene targets patients in remission who have Minimal Residual Disease (MRD), a molecular sign of future relapse. This "consolidation" strategy aims to prevent the cancer's return, a paradigm shift enabled by their therapy's high safety profile and sensitive MRD testing.